Monthly
US$200
Billed every month
Polidocanol Injection(聚多卡醇注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 3 applicationsAccepted: 8 applicationsNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders10View records ↓
Under-review filings23View records ↓
This year’s generic filers4View records ↓
NHSA approval numbers33View records ↓
API companies with A status11View records ↓
Chemical-drug catalogue
Loaded records: 10 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 8 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 苏州朗科生物技术股份有限公司 | 江苏华阳制药有限公司 | 国药准字H20264825 | 2026/06/17 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州朗科生物技术股份有限公司 | 江苏华阳制药有限公司 | 国药准字H20264826 | 2026/06/17 | 2ml：60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州朗科生物技术股份有限公司 | 江苏华阳制药有限公司 | 国药准字H20264824 | 2026/06/17 | 2ml：10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南合瑞制药股份有限公司 | 海南合瑞制药股份有限公司 | 国药准字H20264576 | 2026/05/27 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南合瑞制药股份有限公司 | 海南合瑞制药股份有限公司 | 国药准字H20264577 | 2026/05/27 | 2ml：60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团庆余堂制药有限公司 | 福安药业集团庆余堂制药有限公司 | 国药准字H20264466 | 2026/05/19 | 2ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团庆余堂制药有限公司 | 福安药业集团庆余堂制药有限公司 | 国药准字H20264467 | 2026/05/19 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团庆余堂制药有限公司 | 福安药业集团庆余堂制药有限公司 | 国药准字H20264468 | 2026/05/19 | 2ml:60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海鸿恒隆（海南）生物科技有限公司 | 广东星昊药业有限公司 | 国药准字H20263829 | 2026/04/07 | 2ml:60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海鸿恒隆（海南）生物科技有限公司 | 广东星昊药业有限公司 | 国药准字H20263828 | 2026/04/07 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北汇德旭盛医药科技有限公司 | 河北仁合益康药业有限公司 | 国药准字H20263092 | 2026/01/14 | 2ml：60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北汇德旭盛医药科技有限公司 | 河北仁合益康药业有限公司 | 国药准字H20263091 | 2026/01/14 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州沐源生物医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20255764 | 2025/10/21 | 2ml：60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州沐源生物医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20255766 | 2025/10/21 | 2ml：10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州沐源生物医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20255765 | 2025/10/21 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西天宇制药有限公司 | 陕西天宇制药有限公司 | 国药准字H20258098 | 2025/06/09 | 2ml∶10mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 陕西天宇制药有限公司 | 陕西天宇制药有限公司 | 国药准字H20258100 | 2025/06/09 | 2ml∶20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 陕西天宇制药有限公司 | 陕西天宇制药有限公司 | 国药准字H20258099 | 2025/06/09 | 2ml∶60mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 陕西天宇制药有限公司 | 陕西天宇制药有限公司 | 国药准字H20080445 | 2025/03/13 | 10ml∶0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20243817 | 2024/05/28 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20243818 | 2024/05/28 | 2ml：60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20233934 | 2023/07/25 | 2ml：10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20233935 | 2023/07/25 | 2ml：60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20233936 | 2023/07/25 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Chemische Fabrik Kreussler & Co.GmbH | Hameln pharmaceuticals GmbH | H20160033 | 2013/09/17 | 2ml:20mg | Imported originator drug (进口原研药品) | CDE |
| Chemische Fabrik Kreussler & Co.GmbH | Hameln pharmaceuticals GmbH | H20160034 | 2013/09/17 | 2ml:60mg | Imported originator drug (进口原研药品) | CDE |
| Chemische Fabrik Kreussler & Co.GmbH | Hameln pharmaceuticals GmbH | H20160032 | 2013/09/17 | 10mg/2ml | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 33 distinct approval numbers and 12 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 南京正大天晴制药有限公司 | 国药准字H20233934 | 2ml:10mg | Category B (乙) | XC05BBJ209B002010101606 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20264468 | 2ml:60mg | Category B (乙) | XC05BBJ209B002010101877 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258098 | 2ml:10mg | Category B (乙) | XC05BBJ209B002010102433 | NHSA |
| 哈尔滨誉衡制药有限公司 | 国药准字H20265306 | 2ml:20mg | Category B (乙) | XC05BBJ209B002010103687 | NHSA |
| 海南合瑞制药股份有限公司 | 国药准字H20264577 | 2ml:60mg | Category B (乙) | XC05BBJ209B002010105815 | NHSA |
| Siegfried Hameln GmbH | H20160032 | 10mg/2ml | Category B (乙) | XC05BBJ209B002010179577 | NHSA |
| 苏州朗科生物技术股份有限公司 | 国药准字H20264824 | 2ml:10mg | Category B (乙) | XC05BBJ209B002010183485 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255764 | 2ml:60mg | Category B (乙) | XC05BBJ209B002010184135 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263091 | 2ml:20mg | Category B (乙) | XC05BBJ209B002010184987 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233934 | 2ml:10mg | Category B (乙) | XC05BBJ209B002010201606 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20264468 | 2ml:60mg | Category B (乙) | XC05BBJ209B002010201877 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258098 | 2ml:10mg | Category B (乙) | XC05BBJ209B002010202433 | NHSA |
| 哈尔滨誉衡制药有限公司 | 国药准字H20265306 | 2ml:20mg | Category B (乙) | XC05BBJ209B002010203687 | NHSA |
| 海南合瑞制药股份有限公司 | 国药准字H20264577 | 2ml:60mg | Category B (乙) | XC05BBJ209B002010205815 | NHSA |
| 海鸿恒隆(海南)生物科技有限公司 | 国药准字H20263828 | 2ml:20mg | Category B (乙) | XC05BBJ209B002010283298 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255764 | 2ml:60mg | Category B (乙) | XC05BBJ209B002010284135 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263091 | 2ml:20mg | Category B (乙) | XC05BBJ209B002010284987 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233934 | 2ml:10mg | Category B (乙) | XC05BBJ209B002010301606 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258098 | 2ml:10mg | Category B (乙) | XC05BBJ209B002010302433 | NHSA |
| 海鸿恒隆(海南)生物科技有限公司 | 国药准字H20263828 | 2ml:20mg | Category B (乙) | XC05BBJ209B002010383298 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255764 | 2ml:60mg | Category B (乙) | XC05BBJ209B002010384135 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263091 | 2ml:20mg | Category B (乙) | XC05BBJ209B002010384987 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233934 | 2ml:10mg | Category B (乙) | XC05BBJ209B002010401606 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263091 | 2ml:20mg | Category B (乙) | XC05BBJ209B002010484987 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233935 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020101606 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20264467 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020101877 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258099 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020102433 | NHSA |
| 哈尔滨誉衡制药有限公司 | 国药准字H20265305 | 2ml:10mg | Category B (乙) | XC05BBJ209B002020103687 | NHSA |
| 海南合瑞制药股份有限公司 | 国药准字H20264576 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020105815 | NHSA |
| Siegfried Hameln GmbH | H20160033 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020179577 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243817 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020183033 | NHSA |
| 海鸿恒隆(海南)生物科技有限公司 | 国药准字H20263829 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020183298 | NHSA |
| 苏州朗科生物技术股份有限公司 | 国药准字H20264825 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020183485 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255765 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020184135 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263092 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020184987 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233935 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020201606 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20264467 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020201877 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258099 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020202433 | NHSA |
| 哈尔滨誉衡制药有限公司 | 国药准字H20265305 | 2ml:10mg | Category B (乙) | XC05BBJ209B002020203687 | NHSA |
| 海南合瑞制药股份有限公司 | 国药准字H20264576 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020205815 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243817 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020283033 | NHSA |
| 海鸿恒隆(海南)生物科技有限公司 | 国药准字H20263829 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020283298 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255765 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020284135 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263092 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020284987 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233935 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020301606 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258099 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020302433 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243817 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020383033 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255765 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020384135 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263092 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020384987 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233935 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020401606 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243817 | 2ml:20mg | Category B (乙) | XC05BBJ209B002020483033 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263092 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020484987 | NHSA |
| 河北汇德旭盛医药科技有限公司 | 国药准字H20263092 | 2ml:60mg | Category B (乙) | XC05BBJ209B002020584987 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233936 | 2ml:20mg | Category B (乙) | XC05BBJ209B002030101606 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20264466 | 2ml:10mg | Category B (乙) | XC05BBJ209B002030101877 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258100 | 2ml:20mg | Category B (乙) | XC05BBJ209B002030102433 | NHSA |
| 哈尔滨誉衡制药有限公司 | 国药准字H20265307 | 2ml:60mg | Category B (乙) | XC05BBJ209B002030103687 | NHSA |
| Siegfried Hameln GmbH | H20160034 | 2ml:60mg | Category B (乙) | XC05BBJ209B002030179577 | NHSA |
| 苏州朗科生物技术股份有限公司 | 国药准字H20264826 | 2ml:60mg | Category B (乙) | XC05BBJ209B002030183485 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255766 | 2ml:10mg | Category B (乙) | XC05BBJ209B002030184135 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233936 | 2ml:20mg | Category B (乙) | XC05BBJ209B002030201606 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20264466 | 2ml:10mg | Category B (乙) | XC05BBJ209B002030201877 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258100 | 2ml:20mg | Category B (乙) | XC05BBJ209B002030202433 | NHSA |
| 哈尔滨誉衡制药有限公司 | 国药准字H20265307 | 2ml:60mg | Category B (乙) | XC05BBJ209B002030203687 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255766 | 2ml:10mg | Category B (乙) | XC05BBJ209B002030284135 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233936 | 2ml:20mg | Category B (乙) | XC05BBJ209B002030301606 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20258100 | 2ml:20mg | Category B (乙) | XC05BBJ209B002030302433 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20255766 | 2ml:10mg | Category B (乙) | XC05BBJ209B002030384135 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20233936 | 2ml:20mg | Category B (乙) | XC05BBJ209B002030401606 | NHSA |
| 陕西天宇制药有限公司 | 国药准字H20080445 | 10ml:0.1g | Category B (乙) | XC05BBJ209B002040102433 | NHSA |
| Chemische Fabrik Kreussler & Co. GmbH | 国药准字HJ20160033 | 20mg/2ml | Category B (乙) | XC05BBJ209B002040179577 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243818 | 2ml:60mg | Category B (乙) | XC05BBJ209B002040183033 | NHSA |
| Chemische Fabrik Kreussler & Co. GmbH | 国药准字HJ20160033 | 20mg/2ml | Category B (乙) | XC05BBJ209B002040279577 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243818 | 2ml:60mg | Category B (乙) | XC05BBJ209B002040283033 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243818 | 2ml:60mg | Category B (乙) | XC05BBJ209B002040383033 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243818 | 2ml:60mg | Category B (乙) | XC05BBJ209B002040483033 | NHSA |
| Chemische Fabrik Kreussler & Co. GmbH | 国药准字HJ20160034 | 60mg/2ml | Category B (乙) | XC05BBJ209B002050179577 | NHSA |
| Chemische Fabrik Kreussler & Co. GmbH | 国药准字HJ20160034 | 60mg/2ml | Category B (乙) | XC05BBJ209B002050279577 | NHSA |
| Chemische Fabrik Kreussler & Co. GmbH | 国药准字HJ20160032 | 10mg/2ml | Category B (乙) | XC05BBJ209B002060179577 | NHSA |
| Chemische Fabrik Kreussler & Co. GmbH | 国药准字HJ20160032 | 10mg/2ml | Category B (乙) | XC05BBJ209B002060279577 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 23 filings and 10 distinct first applicants.
Generic 21 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江尖峰药业有限公司 | CYHS2602283 | Generic | 2026/09/14 | Not stated by source | CDE |
| 浙江尖峰药业有限公司 | CYHS2602282 | Generic | 2026/09/14 | Not stated by source | CDE |
| 浙江尖峰药业有限公司 | CYHS2602281 | Generic | 2026/09/14 | Not stated by source | CDE |
| 山东新华制药股份有限公司 | CYHS2601100 | Generic | 2026/05/13 | Not stated by source | CDE |
| 山东新华制药股份有限公司 | CYHS2601099 | Generic | 2026/05/13 | Not stated by source | CDE |
| 浙江华海药业股份有限公司 | CYHS2600093 | Generic | 2026/01/07 | Not stated by source | CDE |
| 浙江华海药业股份有限公司 | CYHS2600092 | Generic | 2026/01/07 | Not stated by source | CDE |
| 珠海前列药业有限公司;湖南华纳大药厂股份有限公司 | CYHS2503501 | Generic | 2025/09/24 | Not stated by source | CDE |
| 珠海前列药业有限公司;湖南华纳大药厂股份有限公司 | CYHS2503500 | Generic | 2025/09/24 | Not stated by source | CDE |
| 浙江赛默制药有限公司 | CYHS2503439 | Generic | 2025/09/17 | Not stated by source | CDE |
| 浙江赛默制药有限公司 | CYHS2503438 | Generic | 2025/09/17 | Not stated by source | CDE |
| 安徽长江药业有限公司 | CYHS2503289 | Generic | 2025/09/05 | Not stated by source | CDE |
| 安徽长江药业有限公司 | CYHS2503288 | Generic | 2025/09/05 | Not stated by source | CDE |
| 安徽长江药业有限公司 | CYHS2503287 | Generic | 2025/09/05 | Not stated by source | CDE |
| 北京双鹭药业股份有限公司 | CYHS2503236 | Generic | 2025/09/03 | Not stated by source | CDE |
| 成都倍特药业股份有限公司 | CYHS2503120 | Generic | 2025/08/26 | Not stated by source | CDE |
| 成都倍特药业股份有限公司 | CYHS2503119 | Generic | 2025/08/26 | Not stated by source | CDE |
| 成都倍特药业股份有限公司 | CYHS2503118 | Generic | 2025/08/26 | Not stated by source | CDE |
| 通化谷红制药有限公司 | CYHS2602646 | Generic | 2026/10/29 | Not stated by source | CDE |
| 通化谷红制药有限公司 | CYHS2602645 | Generic | 2026/10/29 | Not stated by source | CDE |
| 通化谷红制药有限公司 | CYHS2602644 | Generic | 2026/10/29 | Not stated by source | CDE |
| 湖南华纳大药厂股份有限公司 | CYHB2602022 | Supplement | 2026/11/06 | Not stated by source | CDE |
| 湖南华纳大药厂股份有限公司 | CYHB2602021 | Supplement | 2026/11/06 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 10 filings and 4 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江尖峰药业有限公司 | CYHS2602283 | Generic | 2026/09/14 | Not stated by source | CDE |
| 浙江尖峰药业有限公司 | CYHS2602282 | Generic | 2026/09/14 | Not stated by source | CDE |
| 浙江尖峰药业有限公司 | CYHS2602281 | Generic | 2026/09/14 | Not stated by source | CDE |
| 山东新华制药股份有限公司 | CYHS2601100 | Generic | 2026/05/13 | Not stated by source | CDE |
| 山东新华制药股份有限公司 | CYHS2601099 | Generic | 2026/05/13 | Not stated by source | CDE |
| 浙江华海药业股份有限公司 | CYHS2600093 | Generic | 2026/01/07 | Not stated by source | CDE |
| 浙江华海药业股份有限公司 | CYHS2600092 | Generic | 2026/01/07 | Not stated by source | CDE |
| 通化谷红制药有限公司 | CYHS2602646 | Generic | 2026/10/29 | Not stated by source | CDE |
| 通化谷红制药有限公司 | CYHS2602645 | Generic | 2026/10/29 | Not stated by source | CDE |
| 通化谷红制药有限公司 | CYHS2602644 | Generic | 2026/10/29 | Not stated by source | CDE |
API registrations
Non-component matches: 11 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 聚多卡醇 | 浙江赛默制药有限公司 | Y20250000611 | I | Exact ingredient | 2025/07/08 | CDE |
| 聚多卡醇 | 浙江北生药业汉生制药有限公司 | Y20250000345 | A | Exact ingredient | 2026/10/29 | CDE |
| 聚多卡醇 | 四川泰恩康制药有限公司 | Y20250000296 | A | Exact ingredient | 2026/10/17 | CDE |
| 聚多卡醇 | 郑州泰丰制药有限公司 | Y20250000021 | A | Exact ingredient | 2026/10/12 | CDE |
| 聚多卡醇 | 新乡双鹭药业有限公司 | Y20240001495 | I | Exact ingredient | 2025/01/21 | CDE |
| 聚多卡醇 | 海南合瑞制药股份有限公司 | Y20240001509 | A | Exact ingredient | 2026/06/23 | CDE |
| 聚多卡醇 | 连云港贵科药业有限公司 | Y20240001301 | A | Exact ingredient | 2026/08/04 | CDE |
| 聚多卡醇 | 四川仁安药业有限责任公司 | Y20240001038 | A | Exact ingredient | 2026/07/01 | CDE |
| 聚多卡醇 | 江苏暨明医药科技有限公司 | Y20240001037 | A | Exact ingredient | 2026/05/20 | CDE |
| 聚多卡醇 | 济宁神州医药有限公司 | Y20240000750 | A | Exact ingredient | 2026/07/31 | CDE |
| 聚多卡醇 | 河北安健成益医药科技有限公司 | Y20220000760 | A | Exact ingredient | 2024/05/21 | CDE |
| 聚多卡醇 | 南京威尔药业集团股份有限公司 | Y20210000529 | A | Exact ingredient | 2024/01/17 | CDE |
| 聚多卡醇 | 陕西天宇制药有限公司 | Y20190007014 | A | Exact ingredient | 2026/06/22 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/06Accepted
-
2026/11/06Accepted
-
2026/11/04No longer listed under review
西洲医药科技（浙江）有限公司;浙江北生药业汉生制药有限公司
CYHS2501806
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2025/05/17
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/29Accepted
-
2026/10/29Accepted
-
2026/10/29Accepted
-
2026/10/20Marketing application approved
河南泰丰生物科技有限公司
CYHS2500624 · 国药准字H20266306
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 31 ↗ -
2026/10/20Marketing application approved
河南泰丰生物科技有限公司
CYHS2500623 · 国药准字H20266305
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 30 ↗ -
2026/10/20Marketing application approved
河南泰丰生物科技有限公司
CYHS2500622 · 国药准字H20266304
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 29 ↗ -
2026/09/14Accepted
-
2026/09/14Accepted
-
2026/09/14Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Polidocanol Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy